Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term separate and combined effects of GIP and GLP-1 receptor activation in type 2 diabetes
2020-004774-22Phase 2Completed
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of glucose-dependent insulinotropic polypeptide[1-42] and semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Herlev & Gentofte Hospital. Primary endpoint: Change in 14-day mean glucose levels. Started Mar 2021; status: completed.
02
Drugs
glucose-dependent insulinotropic polypeptide[1-42]semaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2020-004774-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004774-22.